CLINICAL & PIPELINE·Drug Approval
FDA Accepts Genentech's sBLA for Lunsumio VELO + Polivy in R/R LBCL: Commercial and Supply Chain Implications
The US FDA's acceptance of Genentech's sBLA for Lunsumio VELO (mosunetuzumab-axgb; SC) + Polivy in relapsed/refractory Large B-Cell Lymphoma signals a significant market opportunity. With a PDUFA date of February 9, 2027, this combination offers a potential new treatment option, impacting procurement strategies and competitive dynamics in the oncology sector.
90-Day Activity